Virpax Pharmaceuticals company info

What does Virpax Pharmaceuticals do?
Virpax Pharmaceuticals (NASDAQ:VRPX) specializes in developing innovative pharmaceutical solutions aimed at improving patient outcomes in pain management and other critical therapeutic areas. The company focuses on creating and advancing a diverse portfolio of product candidates using proprietary delivery technologies designed to enhance patients' lives while addressing the limitations of current treatments. Their projects span a range of formulations and delivery methods, including non-opioid pain management options and therapies for central nervous system disorders, reflecting their commitment to tackling some of the most pressing healthcare challenges. With a goal to revolutionize pain management and ensure better therapeutic efficacy, Virpax Pharmaceuticals is dedicated to pushing the boundaries of science to find new ways to serve patients and the medical community.
Virpax Pharmaceuticals company media
Company Snapshot

Is Virpax Pharmaceuticals a public or private company?

key
Ownership
Public

How many people does Virpax Pharmaceuticals employ?

people
Employees
7

What sector is Virpax Pharmaceuticals in?

pie chart
Sector
Health Care

Where is the head office for Virpax Pharmaceuticals?

location pin
Head Office
Berwyn, United States

What year was Virpax Pharmaceuticals founded?

founded flag
Year Founded
2016
What does Virpax Pharmaceuticals specialise in?
/Pain Management /Pharmaceutical Products /Drug Delivery Technology /Non-Addictive Analgesics /Anti-Viral Therapies /Clinical Research

What are the products and/or services of Virpax Pharmaceuticals?

Overview of Virpax Pharmaceuticals offerings
Envelta™, an opioid-free pain management product aiming to address severe pain with a non-addictive formulation.
Probudur™, a long-acting liposomal bupivacaine formulation designed for post-operative pain relief.
Epoladerm™, a diclofenac epolamine spray film for acute pain, offering targeted, non-opioid pain management.
AnQlar™, an antiviral nasal spray for the prevention of viral replication in nasal passages.
OSF200, a cannabidiol-based product intended for pain management without the psychoactive effects of THC.
MMS019, a high-density molecular masking spray for airborne viruses, aiming to reduce transmission and infection rates.

Who is in the executive team of Virpax Pharmaceuticals?

Virpax Pharmaceuticals leadership team
  • Mr. Gerald W. Bruce
    Mr. Gerald W. Bruce
    CEO & Director
  • Dr. Sheila A. Mathias J.D., M.B.A., Ph.D.
    Dr. Sheila A. Mathias J.D., M.B.A., Ph.D.
    Chief Scientific Officer
  • Dr. Jeffrey A. Gudin M.D.
    Dr. Jeffrey A. Gudin M.D.
    Executive VP, Chief Medical Officer & Director
  • Mr. Vinay  Shah A.C.A., M.B.A.
    Mr. Vinay Shah A.C.A., M.B.A.
    CFO, Principal Financial Officer, Principal Accounting Officer & Corporate Secretary
  • Ms. Shana  Panzarella
    Ms. Shana Panzarella
    Chief of Staff